Caribou Biosciences, Inc. CRBU
Set alert
As of Nov 2, 12:19 PM ET
- YTD
- -72.52%
- 1 year
- -81.95%
- Open
- 0.4346
- Prev close
- 0.4232
- Mkt cap
- 46.59M
- Vol
- 1.64M
- Avg vol
- 2.59M
- EPS
- -1.08
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.41
- High
- 0.4498
- Forward P/E
- -0.90
- Beta
- 2.26
- Short ratio
- 4.55
- Inst. own
- 62.49%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 6, 2024
- 50-d avg
- 2.08
- 200-d avg
- 2.67
- 1y target
- 12.50
5D chart
Signals (104)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 9:30 AM | 2 hours ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:00 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 30, 12:25 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 3 days ago |
| RSI: Oversold | Oct 30, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:20 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:55 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:20 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 9:40 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:35 AM | 3 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:20 PM | 3 days ago |
| RSI: Oversold | Oct 29, 3:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:30 PM | 3 days ago |
| RSI: Oversold | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:50 PM | 3 days ago |
| RSI: Oversold | Oct 29, 1:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 29, 1:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 1:00 PM | 4 days ago |
| RSI: Oversold | Oct 29, 12:30 PM | 4 days ago |
| SMA: Bearish | Oct 29, 10:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 29, 10:10 AM | 4 days ago |
| SMA: Bearish | Oct 29, 10:00 AM | 4 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 5 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 28, 12:20 PM | 5 days ago |
| SMA: Bearish | Oct 28, 12:10 PM | 5 days ago |
| SMA: Bullish | Oct 28, 11:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 28, 11:25 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 5 days ago |
| SMA: Bearish | Oct 28, 11:05 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:00 AM | 5 days ago |
| SMA: Bullish | Oct 28, 11:00 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:50 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 28, 10:20 AM | 5 days ago |
| SMA: Bullish | Oct 28, 10:15 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 28, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 28, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 28, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:25 PM | 5 days ago |
| RSI: Oversold | Oct 27, 3:10 PM | 5 days ago |
| RSI: Oversold | Oct 27, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:45 PM | 6 days ago |
| SMA: Bullish | Oct 27, 12:25 PM | 6 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 6 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 6 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 6 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 6 days ago |
News
3 weeks ago benzinga.com
Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy
Major M&A deals this week include Viatris buys Pacira BioSciences, TowneBank acquires blueharbor, Energy Transfer buys Vacquero Midstream.
3 weeks ago benzinga.com
This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Analysts downgraded Voya, Pacira, Genworth, and more, with price-target changes for several.
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Pacira BioSciences (NASDAQ:PCRX) shares moved upwards by 44.0% to $36.3 during Thursday's regular session. The company's market cap stands at $1.0 billion. Onconetix (NASDAQ:ONCO) stock rose…
3 weeks ago benzinga.com
This Tyler Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Analysts downgraded STZ, TYL, DK, CRBU and PSX; price targets changed for STZ, TYL, DK and PSX.
3 weeks ago benzinga.com
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.
-
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 186.0% to $3.58 during Wednesday's regular session. Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 151.31% to $1.0. The…
3 weeks ago benzinga.com
Nasdaq Falls Over 100 Points; US Crude Inventories Decline
U.S. stocks fell Wednesday, led by industrials. Crude inventories dropped unexpectedly, while Penguin Solutions and Lipocine surged; Caribou Biosciences
3 weeks ago benzinga.com
This Option Care Health Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
Analysts downgraded PJT, OPCH, CRBU, ABEV , cutting price targets for PJT, CRBU.
3 weeks ago benzinga.com
Dow Tumbles 350 Points; Constellation Brands Earnings Top Views
U.S. stocks fell Wednesday; Dow dropped 350 points. Energy rose, materials slid. Constellation beat estimates; oil gained while gold and silver fell.
-
3 weeks ago benzinga.com
RBC Capital Downgrades Caribou Biosciences to Sector Perform, Lowers Price Target to $1
RBC Capital analyst Luca Issi downgrades Caribou Biosciences (NASDAQ:CRBU) from Outperform to Sector Perform and lowers the price target from $10 to $1.
3 weeks ago benzinga.com
Stock Market Today: S&P 500, Dow, Nasdaq Futures Fall as 30-Year Treasury Yield Hits 2002 High; Iran Mocks US Economy — STZ, PENG, LEVI in Focus (UPDATED)
U.S. stock futures were lower on Wednesday, as the Dow Jones, S&P 500 and Nasdaq 100 indices fell, following Tuesday's higher close.
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 59.2% to $1.99 during Wednesday's pre-market session. Lipocine (NASDAQ:LPCN) shares rose 52.38% to $3.2. The company's market cap…
-
3 weeks ago benzinga.com
Leerink Partners Downgrades Caribou Biosciences to Market Perform, Lowers Price Target to $1
Leerink Partners analyst Daina Graybosch downgrades Caribou Biosciences (NASDAQ:CRBU) from Outperform to Market Perform and lowers the price target from $4 to $1.
3 weeks ago benzinga.com
Constellation Brands, Caribou Biosciences And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. stock futures fell; Constellation Brands dropped 5.1% despite beating estimates, while biotech, mining and other stocks declined premarket.
3 weeks ago benzinga.com
Why Penguin Solutions Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
Penguin Solutions jumped 7.7% after beating Q4 revenue/EPS estimates and issuing above-consensus FY27 EPS guidance.
3 weeks ago benzinga.com
Levi Strauss, Constellation Brands and 3 Stocks to Watch Heading Into Wednesday
Stocks in focus: Levi Strauss and Applied Digital report earnings; Caribou halts programs; Constellation raises guidance; Richardson reports.
3 weeks ago benzinga.com
Caribou Biosciences (CRBU) Shares Fall 35% After Hours: Here's Why
Caribou Biosciences shares fall 35% after hours as the company weighs strategic alternatives and cuts two drug programs.
-
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 64.0% to $2.05 during Tuesday's after-market session. The market value of their outstanding shares is at $1.1 million. Neogen…
-
3 weeks ago benzinga.com
Caribou Biosciences Mulls Strategic Options To Maximize Shareholder Value; Intends To Discontinue Further Development Activities For Two Allogeneic CAR-T Cell Therapy Programs
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that it is exploring strategic alternatives to maximize stockholder…
3 weeks ago globenewswire.com
Caribou Biosciences to Evaluate Strategic Alternatives
-- Company to evaluate strategic alternatives to maximize stockholder value -- -- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs --
1 month ago zacks.com
Caribou Biosciences (CRBU) Loses 19.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Caribou Biosciences (CRBU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall…
1 month ago defenseworld.net
BlackRock Inc. Invests $13.76 Million in Caribou Biosciences, Inc. $CRBU
BlackRock Inc. purchased a new stake in shares of Caribou Biosciences, Inc. (NASDAQ: CRBU) during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The…
2 months ago zacks.com
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Top-ranked stocks ALL, W, BILL, TWLO and CRBU are likely to beat on the bottom line in their upcoming releases.
2 months ago defenseworld.net
Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $7.75
Caribou Biosciences, Inc. (NASDAQ: CRBU - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are currently covering the company, MarketBeat.com…
-
2 months ago benzinga.com
B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $5
B of A Securities analyst Alec Stranahan maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target from $6 to $5.
2 months ago zacks.com
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.35 per share a year ago.
-
2 months ago benzinga.com
Caribou Biosciences Q2 EPS $(0.24) Beats $(0.32) Estimate, Sales $1.499M Miss $2.279M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.32) by 25 percent. This is a 31.43 percent increase over losses of…
2 months ago globenewswire.com
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to…
3 months ago zacks.com
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their sector so far this year.
4 months ago globenewswire.com
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel…
-
4 months ago benzinga.com
Caribou Biosciences Reports Longer Follow Up Data For Ongoing CaMMouflage Phase 1 Trial Of CB-011, Off-The-Shelf BCMA-Targeted CAR-T Cell Therapy, Being Evaluated For r/r MM
-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months ---- Case…
4 months ago globenewswire.com
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient…
4 months ago globenewswire.com
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case…
4 months ago marketbeat.com
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
Caribou Biosciences NASDAQ: CRBU Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate…
4 months ago seekingalpha.com
Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript
5 months ago globenewswire.com
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,…
5 months ago seekingalpha.com
Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Transcript
5 months ago globenewswire.com
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou's…
-
5 months ago benzinga.com
Caribou Biosciences To Present Phase 1 CAR-T Therapy Data For vispa-cel And CB-011 At EHA 2026 Annual Meeting
Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for oral presentations at the 2026…
5 months ago globenewswire.com
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts…
-
5 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Raises Price Target to $11
HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and raises the price target from $9 to $11.
5 months ago zacks.com
Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.43 per share a year ago.
-
5 months ago benzinga.com
Caribou Biosciences Q1 EPS $(0.26) Beats $(0.31) Estimate, Sales $2.397M Beat $2.241M Estimate
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.31) by 16.13 percent. This is a 39.53 percent increase over losses of…
5 months ago globenewswire.com
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 -- --…
-
12 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 months ago benzinga.com
Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
2 years ago benzinga.com
Investor Sentiment Improves Following Inflation Data, Dow Jumps Over 200 Points
The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, but the index remained in the "Greed" zone on Tuesday.
-
2 years ago benzinga.com
Gold Down Over 1%; ClearOne Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on Tuesday. The Dow traded up 0.74% to 39,057.10 while the NASDAQ rose 1.41% to 16,245.83. The S&P 500 also…
-
2 years ago benzinga.com
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.